

Translation

TENT COOPERATION TREATY

Rec'd PCT 11 MAR 2003

PCT/JP2003/011834



INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY
(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference ONF-4710PCT	FOR FURTHER ACTION	See Form PCT/IPEA/416
International application No. PCT/JP2003/011834	International filing date (day/month/year) 17 September 2003 (17.09.2003)	Priority date (day/month/year) 18 September 2002 (18.09.2002)
International Patent Classification (IPC) or national classification and IPC C07D 471/10, A61K 31/527, A61P 1/04, 1/16, 3/10, 9/00, 11/00, 11/02, 11/06, 13/12, 17/00, 17/06, 19/02, 29/00, 31/04, 31/18, 35/04, 37/02, 37/06, 37/08, 43/00, 25/00, 27/00		
Applicant ONO PHARMACEUTICAL CO., LTD.		

1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 5 sheets, including this cover sheet.
3. This report is also accompanied by ANNEXES, comprising:
 - a. ☐ (sent to the applicant and to the International Bureau) a total of _____ sheets, as follows:
 - ☐ sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).
 - ☐ sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.
 - b. ☐ (sent to the International Bureau only) a total of _____, containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).
4. This report contains indications relating to the following items:

<input checked="" type="checkbox"/> Box No. I	Basis of the report
<input type="checkbox"/> Box No. II	Priority
<input checked="" type="checkbox"/> Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
<input type="checkbox"/> Box No. IV	Lack of unity of invention
<input checked="" type="checkbox"/> Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
<input checked="" type="checkbox"/> Box No. VI	Certain documents cited
<input type="checkbox"/> Box No. VII	Certain defects in the international application
<input type="checkbox"/> Box No. VIII	Certain observations on the international application

Date of submission of the demand 12 March 2004 (12.03.2004)	Date of completion of this report 22 July 2004 (22.07.2004)
Name and mailing address of the IPEA/JP	Authorized officer
Facsimile No.	Telephone No.

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International Application No.

PCT/JP2003/011834

Box No. I Basis of the report

1. With regard to the language, this report is based on the international application in the language in which it was filed, unless otherwise indicated under this item.

- ☐ This report is based on translations from the original language into the following language _____, which is language of a translation furnished for the purpose of:
- ☐ international search (under Rules 12.3 and 23.1(b))
 - ☐ publication of the international application (under Rule 12.4)
 - ☐ international preliminary examination (under Rules 55.2 and/or 55.3)

2. With regard to the elements of the international application, this report is based on *(replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report)*:

- ☒ The international application as originally filed/furnished
- ☐ the description:
pages _____, as originally filed/furnished
pages* _____ received by this Authority on _____
pages* _____ received by this Authority on _____
- ☐ the claims:
pages _____, as originally filed/furnished
pages* _____, as amended (together with any statement) under Article 19
pages* _____ received by this Authority on _____
pages* _____ received by this Authority on _____
- ☐ the drawings:
pages _____, as originally filed/furnished
pages* _____ received by this Authority on _____
pages* _____ received by this Authority on _____
- ☐ a sequence listing and/or any related table(s) – see Supplemental Box Relating to Sequence Listing.

3. ☐ The amendments have resulted in the cancellation of:

- ☐ the description, pages _____
- ☐ the claims, Nos. _____
- ☐ the drawings, sheets/figs _____
- ☐ the sequence listing (*specify*): _____
- ☐ any table(s) related to sequence listing (*specify*): _____

4. ☐ This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).

- ☐ the description, pages _____
- ☐ the claims, Nos. _____
- ☐ the drawings, sheets/figs _____
- ☐ the sequence listing (*specify*): _____
- ☐ any table(s) related to sequence listing (*specify*): _____

* If item 4 applies, some or all of those sheets may be marked "superseded."

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International Application No.

PCT/JP03/11834

Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application.

☒ claim No. 12

because:

☒ the said international application, or the said claim No. 12
relates to the following subject matter which does not require an international preliminary examination (*specify*):

The invention of claim 12 relates to a method for treatment of the human body.

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. _____
are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. _____ are so inadequately supported
by the description that no meaningful opinion could be formed.

☒ no international search report has been established for said claim No. 12

☐ the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the
Administrative Instructions in that:

the written form

☐ has not been furnished

☐ does not comply with the standard

the computer readable form

☐ has not been furnished

☐ does not comply with the standard

☐ the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with
the technical requirements provided for in Annex C-bis of the Administrative Instructions.

☐ see Supplemental Box for further details.

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. Statement**


Novelty (N)	Claims		YES
	Claims	1-11, 13	NO
Inventive step (IS)	Claims		YES
	Claims	1-11, 13	NO
Industrial applicability (IA)	Claims	1-11, 13	YES
	Claims		NO

2. Citations and explanations (Rule 70.7)

Document 1 [WO, 01/40227, A1 (Ono Pharmaceutical Co., Ltd.), 07 June, 2001] describes a compound represented by General Formula (I), which is a duplicate compound of the compound represented by General Formula (I) of this application; document 1 shows that this compound inhibits chemokine / chemokine receptor action and is effective for inflammatory diseases, etc.

Document 2: MEADA, K. et al., "Novel low molecular weight spirodiketoperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5", Journal of Biological Chemistry, 276 (37), pages 35194 to 35200 (2001)

The compounds below are described as CCR5 antagonists.

**Claims 1-11, 13**

The inventions described in claims 1-11 and 13 do not appear to be novel or to involve an inventive step based on documents 1 and 2 cited in the ISR.

A duplicate compound of the compound described in claim 1 of this application is shown in documents 1 and 2 and the compound being effective for inflammatory diseases (in document 1) and the compound being a CCR antagonist (in document 2) are also shown.

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International Application No.

PCT/JP03/11834

Box No. VI Certain documents cited

1. Certain published documents (Rule 70.10)

Application No. Patent No.	Publication date (day/month/year)	Filing date (day/month/year)	Priority date (valid claim) (day/month/year)
WO 03/35074 A1 (Ono Pharmaceutical Co., Ltd.) EX	01.05.2003	18.03.2002	23.10.2001
JP 2002-348288 A (Ono Pharmaceutical Co., Ltd.) EX	04.12.2002	28.05.2001	
WO 02/074770 A1 (Ono Pharmaceutical Co., Ltd.) EX	26.09.2002	18.03.2002	19.03.2001
WO 02/074769 A1 (Ono Pharmaceutical Co., Ltd.) EX	26.09.2002	18.03.2002	19.03.2001

2. Non-written disclosures (Rule 70.9)

Kind of non-written disclosure	Date of non-written disclosure (day/month/year)	Date of written disclosure referring to non-written disclosure (day/month/year)
--------------------------------	--	---